The new CONSORT statement-Children and Adolescents (CONSORT-C) 2026 extends the CONSORT 2025 standard to include items specific to the reporting of pediatric randomized controlled trials (RCTs) in children and adolescents aged 0–19 years. RCTs in children and adolescents provide evidence for patients, families, researchers, clinicians, regulators, funders and policy makers to inform health interventions and improve outcomes. CONSORT-C 2026 was developed in collaboration with young people aged 10–24 and family carers. It contains 13 new reporting items that complement the comprehensive reporting of CONSORT 2025. These items improve the transparency, reproducibility, accuracy, and usefulness of published reports of pediatric RCTs. Appropriately designed, well-conducted, and comprehensively reported RCTs support transparent, evidence-based health care decisions.[3]